- 15.09.2011
- Extended Phase II Results for BC-3781
- 18.04.2011
- Positive Results from Phase II Trial
- 10.01.2011
- Completed recruitment of Phase II clinical trial BC-3781
- 10.09.2010
- BC-3781 Shows Therapeutic Potential
- 02.06.2010
- Phase II of pleuromutilin antibiotic BC-3781
- 31.05.2010
- Nabriva nominated as a finalist for the 2010 Red Herring 100 Europe Award
- 12.04.2010
- Nabriva reports successful Phase I clinical trial for BC-3781
- 28.10.2009
- Nabriva Therapeutics raises Euro 15 Million (USD 22 Million)
- 23.07.2009
- Nabriva Therapeutics initiates Clinical Phase I trial of pleuromutilin antibiotic BC-3781
- 07.05.2009
- Nabriva Therapeutics Appoints New Supervisory Board Member
- 27.03.2009
- Nabriva Therapeutics Appoints Dr. David Chiswell as Chief Executive Officer
- 19.01.2009
- Nabriva Therapeutics Appoints Chief Medical Officer
- PRESS RELEASE ARCHIVE
- See Nabriva at the following conferences
- Corporate Factsheet
© Nabriva Therapeutics Forschungs GmbH